文献速递炎症性肠病

维多珠单抗、阿达木单抗与甲氨蝶呤联合治疗克罗恩病(EXPLORER)

Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-09-22

EXPLORER是一项4期单臂开放标签研究,评估维多珠单抗、阿达木单抗与甲氨蝶呤三联疗法用于新诊断、中高危且未接受过生物制剂的克罗恩病患者。55例患者中,第26周内镜缓解率为34.5%,第10周和第26周临床缓解率分别为61.8%和54.5%,6例发生严重不良事件。作者认为该结果支持进一步评估联合治疗。

要点

  • 第26周内镜缓解(SES-CD≤2)19例(34.5%),第10周临床缓解34例(61.8%),第26周临床缓解30例(54.5%)。
  • 事后贝叶斯分析显示三联疗法内镜缓解率高于安慰剂的概率≥99.9%,高于维多珠单抗单药为86.3%,高于阿达木单抗单药为71.4%。
  • 6例患者发生严重不良事件,作者认为未发现与治疗方案相关的安全性信号。

核心结论

  • 联合治疗使第26周内镜缓解和临床缓解率分别达到34.5%和54.5%,未发现与治疗方案相关的安全性信号;作者认为这支持在克罗恩病中进一步评估联合治疗。

研究设计与样本

  • EXPLORER为4期、单臂、开放标签研究,纳入未接受过生物制剂的新诊断、中高危克罗恩病患者55例。
  • 维多珠单抗给药为第1天300 mg、第2周和第6周各300 mg,之后每8周300 mg。
  • 阿达木单抗给药为第2天160 mg、第2周80 mg,之后每2周40 mg。
  • 甲氨蝶呤为每周15 mg。

主要发现

  • 55例入组患者平均克罗恩病病程0.4年,平均基线SES-CD为12.6,平均基线CDAI为265.5。
  • 第26周内镜缓解(SES-CD≤2)19例(34.5%)。
  • 第10周临床缓解(CDAI<150)34例(61.8%),第26周临床缓解30例(54.5%)。
  • 事后贝叶斯分析中,三联疗法内镜缓解率为33.5%(95%可信区间22.4-45.7),高于安慰剂(14%)、维多珠单抗单药(27%)和阿达木单抗单药(30%)的概率分别为99.9%或更高、86.3%和71.4%。
  • 6例患者发生严重不良事件。

关键数值与推荐

  • 主要终点为第26周内镜缓解,定义为SES-CD≤2。
  • 次要终点为第10周和第26周临床缓解,定义为CDAI<150。
  • 同时评估不良事件和严重不良事件的发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although biologics have revolutionized the treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS: EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, and then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly) in biologic-naïve patients with newly diagnosed, moderate- to high-risk CD. Endoscopic remission at week 26 (primary end point; Simple Endoscopic Score for CD ≤2), clinical remission at weeks 10 and 26 (secondary end point; Crohn's Disease Activity Index <150), and incidences of adverse events and serious adverse events were evaluated. RESULTS: Among 55 enrolled patients, the mean CD duration was 0.4 years, the mean baseline Simple Endoscopic Score for CD was 12.6, and the mean baseline Crohn's Disease Activity Index was 265.5. At week 26, 19 patients (34.5%) were in endoscopic remission. At weeks 10 and 26, 34 (61.8%) and 30 patients (54.5%), respectively, were in clinical remission. Post hoc Bayesian analysis showed that the probabilities that triple combination therapy produced a higher endoscopic remission rate (33.5%; 95% credible interval, 22.4-45.7) than placebo (14%), vedolizumab monotherapy (27%), or adalimumab monotherapy (30%) were 99.9% or higher, 86.3%, and 71.4%, respectively. Six patients had serious adverse events. CONCLUSIONS: Combination therapy resulted in endoscopic and clinical remission at week 26 in 34.5% and 54.5% of patients, respectively, with no safety signal related to the treatment regimen. This supports further evaluation of combination therapy in CD. CLINICALTRIALS: gov number: NCT02764762.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Ungaro RC, Sands BE, et al. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clin Gastroenterol Hepatol. 2023. PMID: 37743037. doi:10.1016/j.cgh.2023.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。